Business Context and Reporting Period
Company: OrthoPediatrics Corp. (KIDS)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: OrthoPediatrics is a global medical device company exclusively focused on pediatric orthopedic conditions, offering trauma and deformity correction, scoliosis, sports medicine, and specialty bracing products. The company utilizes a contract manufacturing model for implants and in-house manufacturing for bracing.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Revenue | $52,802 | $39,559 | $97,487 | $71,147 |
| Gross Profit | $40,799 | $30,025 | $72,973 | $53,586 |
| Gross Margin | 77.3% | 75.9% | 74.9% | 75.3% |
| Operating Loss | $(5,666) | $(5,586) | $(15,389) | $(14,177) |
| Net Loss | $(6,029) | $(2,886) | $(13,834) | $(9,692) |
| Diluted EPS | $(0.26) | $(0.13) | $(0.60) | $(0.43) |
| Cash & Equivalents (End of Period) | $28,927 | Balance Sheet Data | ||
| Total Debt (Gross) | $11,217 | Balance Sheet Data | ||
| Accumulated Deficit | $(211,576) | Balance Sheet Data |
Liquidity: As of June 30, 2024, the company held $28.9 million in cash and cash equivalents and $1.96 million in restricted cash. The company maintains an $80 million credit facility with $19.0 million available under the revolving portion as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 33% in Q2 2024 and 37% YTD compared to the prior year. This growth was primarily driven by the acquisition of Boston O&P (closed Jan 2024) and strong performance in Trauma and Deformity and Scoliosis product lines.
- Expense Increases: General and Administrative (G&A) expenses rose 43% in Q2 and 44% YTD, largely due to the integration of Boston O&P and increased stock-based compensation. Sales and Marketing expenses increased 23% in Q2 due to higher commissions and the new acquisition.
- Net Loss Expansion: Net loss widened significantly in Q2 (109% increase) and YTD (43% increase). The Q2 increase was partially offset in the prior year by a $2.3 million fair value adjustment gain on contingent consideration from the ApiFix acquisition, which did not recur in 2024.
- Acquisition Activity: The company acquired Boston Brace International, Inc. (Boston O&P) for $22 million in cash plus restricted stock awards in January 2024, adding pediatric orthotic and prosthetic devices to its portfolio.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Financing (August 2024): On August 5, 2024, the company entered into a new Term Loan Agreement for up to $50 million ($25M initial + $25M delayed draw) and issued $50 million in 4.75% Convertible Senior Notes due 2030. Proceeds will be used to pay existing debt, transaction fees, and fund a $5 million stock repurchase program.
- Stock Repurchase Program: The Board approved a $5 million repurchase program contingent on the closing of the new financing. No shares have been repurchased as of the filing date.
- Legal Proceedings:
- IMED Surgical: Ongoing dispute regarding software ownership (Point & Click). Arbitration was terminated in 2022 due to non-payment by the plaintiff but was reinstated in April 2024; proceedings are pending.
- Boston O&P Litigation: A wrongful death lawsuit involving a patient treated with a Boston O&P brace. Trial is scheduled for December 2025.
- Risks: The company faces risks related to the impact of respiratory viruses (RSV) on elective surgery volumes, regulatory compliance, and the ability to achieve profitability. The company has an accumulated deficit of $211.6 million and expects losses to continue in the near term.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Term Loan and Convertible Notes covenants, specifically the requirement to maintain unrestricted cash equal to 25% of outstanding term loans and minimum net product sales targets.
- Acquisition Integration: Monitor the financial contribution and integration costs of the Boston O&P acquisition to ensure it meets revenue and margin expectations.
- Legal Exposure: Track the status of the IMED Surgical arbitration and the Boston O&P wrongful death lawsuit for potential material adverse effects.
- Cash Burn Rate: Assess the sustainability of the current operating cash burn ($12.8 million used in operations YTD) against the new $50 million in financing proceeds and existing cash reserves.
- Convertible Note Dilution: Evaluate the potential dilution impact of the $50 million convertible notes, which have an initial conversion price of approximately $40.98 per share.